{"id":829378,"date":"2025-03-25T08:08:03","date_gmt":"2025-03-25T12:08:03","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cervomed-announces-oral-presentation-at-19th-international-conference-on-alzheimers-and-parkinsons-diseases-and-related-neurologic-disorders-ap-pd\/"},"modified":"2025-03-25T08:08:03","modified_gmt":"2025-03-25T12:08:03","slug":"cervomed-announces-oral-presentation-at-19th-international-conference-on-alzheimers-and-parkinsons-diseases-and-related-neurologic-disorders-ap-pd","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cervomed-announces-oral-presentation-at-19th-international-conference-on-alzheimers-and-parkinsons-diseases-and-related-neurologic-disorders-ap-pd\/","title":{"rendered":"CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer\u2019s and Parkinson\u2019s Diseases and Related Neurologic Disorders (AP\/PD\u2122)"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">BOSTON, March  25, 2025  (GLOBE NEWSWIRE) &#8212; CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced it will deliver an oral presentation at the 19<sup>th<\/sup> International Conference on Alzheimer\u2019s and Parkinson\u2019s Diseases and Related Neurologic Disorders (AP\/PD\u2122), being held on April 1-5, 2025 in in Vienna, Austria. The Company will be presenting detailed analyses from the Extension Phase of the RewinD-LB Phase 2b study of neflamapimod in dementia with Lewy bodies (DLB).<\/p>\n<p>\n        <strong>Details of the AP\/PD\u2122 presentation are as follow:<\/strong>\n      <\/p>\n<p>\n        <strong>Abstract Title:<\/strong> Efficacy and safety results of the RewinD-LB Phase 2b clinical trial of neflamapimod in dementia with Lewy bodies (DLB)<br \/><strong>Format: <\/strong>Oral Presentation<br \/><strong>Presenters: <\/strong>John Alam, MD, CEO of CervoMed and Co-Principal Investigator of the RewinD-LB Study and Stephen Gomperts, MD, PhD, Associate Professor of Neurology at Harvard Medical School and Director, Lewy Body Dementia Unit at the Massachusetts General Hospital.<br \/><strong>Session Name: <\/strong>Advances in PD, LBD, and MSA Drug Development <br \/><strong>Presentation Date and Time:<\/strong> Saturday, April 5th, 2025, 18.25-18.40 pm CET<\/p>\n<p>The abstract will be accessible in the Investor section of the CervoMed website <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0Zi1WEF7Nwc57N6t1Wnl36Q4jVePHm6QKYsz_0oJiYT7BnpaIoLtD3BxGYqJHQbZIn7ceSXjX2JWueGczqyrkU0avB9yve41080SznUG4Zc=\" rel=\"nofollow\" target=\"_blank\">https:\/\/www.cervomed.com\/<\/a> following the presentation.<\/p>\n<p>\n        <strong>About CervoMed<\/strong><br \/>\n        <br \/>CervoMed is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is currently developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that causes disease in DLB and certain other major neurological disorders. Neflamapimod is currently being evaluated in a Phase 2b trial in patients with DLB.<\/p>\n<p>\n        <strong>Investor Contact: <\/strong><br \/>\n        <br \/>PJ Kelleher<br \/>LifeSci Advisors<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=dATdbVU7NZ6VWhh405Gm1uGquRa_BfqJ4fj484ZZM48JcScfCPVOJSzoq2VJJ5VfSfmEACg9aa4qUTQ3PsLK7ZCHcu1vRXMCUWrTtMGVzsk=\" rel=\"nofollow\" target=\"_blank\">Investors@cervomed.com<\/a><br \/>617-430-7579<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQwOTg5MyM2ODMxNTc5IzUwMDEyMTE2MA==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/M2NkM2MzZDMtYjM3MC00MDk1LWE4YTUtNDZiNjQyNzRkZTkyLTUwMDEyMTE2MC0yMDI1LTAzLTI1LWVu\/tiny\/CervoMed-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BOSTON, March 25, 2025 (GLOBE NEWSWIRE) &#8212; CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced it will deliver an oral presentation at the 19th International Conference on Alzheimer\u2019s and Parkinson\u2019s Diseases and Related Neurologic Disorders (AP\/PD\u2122), being held on April 1-5, 2025 in in Vienna, Austria. The Company will be presenting detailed analyses from the Extension Phase of the RewinD-LB Phase 2b study of neflamapimod in dementia with Lewy bodies (DLB). Details of the AP\/PD\u2122 presentation are as follow: Abstract Title: Efficacy and safety results of the RewinD-LB Phase 2b clinical trial of neflamapimod in dementia with Lewy bodies (DLB)Format: Oral PresentationPresenters: John Alam, MD, CEO of CervoMed and Co-Principal &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cervomed-announces-oral-presentation-at-19th-international-conference-on-alzheimers-and-parkinsons-diseases-and-related-neurologic-disorders-ap-pd\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer\u2019s and Parkinson\u2019s Diseases and Related Neurologic Disorders (AP\/PD\u2122)&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-829378","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer\u2019s and Parkinson\u2019s Diseases and Related Neurologic Disorders (AP\/PD\u2122) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cervomed-announces-oral-presentation-at-19th-international-conference-on-alzheimers-and-parkinsons-diseases-and-related-neurologic-disorders-ap-pd\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer\u2019s and Parkinson\u2019s Diseases and Related Neurologic Disorders (AP\/PD\u2122) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BOSTON, March 25, 2025 (GLOBE NEWSWIRE) &#8212; CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced it will deliver an oral presentation at the 19th International Conference on Alzheimer\u2019s and Parkinson\u2019s Diseases and Related Neurologic Disorders (AP\/PD\u2122), being held on April 1-5, 2025 in in Vienna, Austria. The Company will be presenting detailed analyses from the Extension Phase of the RewinD-LB Phase 2b study of neflamapimod in dementia with Lewy bodies (DLB). Details of the AP\/PD\u2122 presentation are as follow: Abstract Title: Efficacy and safety results of the RewinD-LB Phase 2b clinical trial of neflamapimod in dementia with Lewy bodies (DLB)Format: Oral PresentationPresenters: John Alam, MD, CEO of CervoMed and Co-Principal &hellip; Continue reading &quot;CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer\u2019s and Parkinson\u2019s Diseases and Related Neurologic Disorders (AP\/PD\u2122)&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cervomed-announces-oral-presentation-at-19th-international-conference-on-alzheimers-and-parkinsons-diseases-and-related-neurologic-disorders-ap-pd\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-25T12:08:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQwOTg5MyM2ODMxNTc5IzUwMDEyMTE2MA==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cervomed-announces-oral-presentation-at-19th-international-conference-on-alzheimers-and-parkinsons-diseases-and-related-neurologic-disorders-ap-pd\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cervomed-announces-oral-presentation-at-19th-international-conference-on-alzheimers-and-parkinsons-diseases-and-related-neurologic-disorders-ap-pd\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer\u2019s and Parkinson\u2019s Diseases and Related Neurologic Disorders (AP\\\/PD\u2122)\",\"datePublished\":\"2025-03-25T12:08:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cervomed-announces-oral-presentation-at-19th-international-conference-on-alzheimers-and-parkinsons-diseases-and-related-neurologic-disorders-ap-pd\\\/\"},\"wordCount\":300,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cervomed-announces-oral-presentation-at-19th-international-conference-on-alzheimers-and-parkinsons-diseases-and-related-neurologic-disorders-ap-pd\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQwOTg5MyM2ODMxNTc5IzUwMDEyMTE2MA==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cervomed-announces-oral-presentation-at-19th-international-conference-on-alzheimers-and-parkinsons-diseases-and-related-neurologic-disorders-ap-pd\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cervomed-announces-oral-presentation-at-19th-international-conference-on-alzheimers-and-parkinsons-diseases-and-related-neurologic-disorders-ap-pd\\\/\",\"name\":\"CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer\u2019s and Parkinson\u2019s Diseases and Related Neurologic Disorders (AP\\\/PD\u2122) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cervomed-announces-oral-presentation-at-19th-international-conference-on-alzheimers-and-parkinsons-diseases-and-related-neurologic-disorders-ap-pd\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cervomed-announces-oral-presentation-at-19th-international-conference-on-alzheimers-and-parkinsons-diseases-and-related-neurologic-disorders-ap-pd\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQwOTg5MyM2ODMxNTc5IzUwMDEyMTE2MA==\",\"datePublished\":\"2025-03-25T12:08:03+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cervomed-announces-oral-presentation-at-19th-international-conference-on-alzheimers-and-parkinsons-diseases-and-related-neurologic-disorders-ap-pd\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cervomed-announces-oral-presentation-at-19th-international-conference-on-alzheimers-and-parkinsons-diseases-and-related-neurologic-disorders-ap-pd\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cervomed-announces-oral-presentation-at-19th-international-conference-on-alzheimers-and-parkinsons-diseases-and-related-neurologic-disorders-ap-pd\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQwOTg5MyM2ODMxNTc5IzUwMDEyMTE2MA==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQwOTg5MyM2ODMxNTc5IzUwMDEyMTE2MA==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cervomed-announces-oral-presentation-at-19th-international-conference-on-alzheimers-and-parkinsons-diseases-and-related-neurologic-disorders-ap-pd\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer\u2019s and Parkinson\u2019s Diseases and Related Neurologic Disorders (AP\\\/PD\u2122)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer\u2019s and Parkinson\u2019s Diseases and Related Neurologic Disorders (AP\/PD\u2122) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cervomed-announces-oral-presentation-at-19th-international-conference-on-alzheimers-and-parkinsons-diseases-and-related-neurologic-disorders-ap-pd\/","og_locale":"en_US","og_type":"article","og_title":"CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer\u2019s and Parkinson\u2019s Diseases and Related Neurologic Disorders (AP\/PD\u2122) - Market Newsdesk","og_description":"BOSTON, March 25, 2025 (GLOBE NEWSWIRE) &#8212; CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced it will deliver an oral presentation at the 19th International Conference on Alzheimer\u2019s and Parkinson\u2019s Diseases and Related Neurologic Disorders (AP\/PD\u2122), being held on April 1-5, 2025 in in Vienna, Austria. The Company will be presenting detailed analyses from the Extension Phase of the RewinD-LB Phase 2b study of neflamapimod in dementia with Lewy bodies (DLB). Details of the AP\/PD\u2122 presentation are as follow: Abstract Title: Efficacy and safety results of the RewinD-LB Phase 2b clinical trial of neflamapimod in dementia with Lewy bodies (DLB)Format: Oral PresentationPresenters: John Alam, MD, CEO of CervoMed and Co-Principal &hellip; Continue reading \"CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer\u2019s and Parkinson\u2019s Diseases and Related Neurologic Disorders (AP\/PD\u2122)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cervomed-announces-oral-presentation-at-19th-international-conference-on-alzheimers-and-parkinsons-diseases-and-related-neurologic-disorders-ap-pd\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-25T12:08:03+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQwOTg5MyM2ODMxNTc5IzUwMDEyMTE2MA==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cervomed-announces-oral-presentation-at-19th-international-conference-on-alzheimers-and-parkinsons-diseases-and-related-neurologic-disorders-ap-pd\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cervomed-announces-oral-presentation-at-19th-international-conference-on-alzheimers-and-parkinsons-diseases-and-related-neurologic-disorders-ap-pd\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer\u2019s and Parkinson\u2019s Diseases and Related Neurologic Disorders (AP\/PD\u2122)","datePublished":"2025-03-25T12:08:03+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cervomed-announces-oral-presentation-at-19th-international-conference-on-alzheimers-and-parkinsons-diseases-and-related-neurologic-disorders-ap-pd\/"},"wordCount":300,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cervomed-announces-oral-presentation-at-19th-international-conference-on-alzheimers-and-parkinsons-diseases-and-related-neurologic-disorders-ap-pd\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQwOTg5MyM2ODMxNTc5IzUwMDEyMTE2MA==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cervomed-announces-oral-presentation-at-19th-international-conference-on-alzheimers-and-parkinsons-diseases-and-related-neurologic-disorders-ap-pd\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cervomed-announces-oral-presentation-at-19th-international-conference-on-alzheimers-and-parkinsons-diseases-and-related-neurologic-disorders-ap-pd\/","name":"CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer\u2019s and Parkinson\u2019s Diseases and Related Neurologic Disorders (AP\/PD\u2122) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cervomed-announces-oral-presentation-at-19th-international-conference-on-alzheimers-and-parkinsons-diseases-and-related-neurologic-disorders-ap-pd\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cervomed-announces-oral-presentation-at-19th-international-conference-on-alzheimers-and-parkinsons-diseases-and-related-neurologic-disorders-ap-pd\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQwOTg5MyM2ODMxNTc5IzUwMDEyMTE2MA==","datePublished":"2025-03-25T12:08:03+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cervomed-announces-oral-presentation-at-19th-international-conference-on-alzheimers-and-parkinsons-diseases-and-related-neurologic-disorders-ap-pd\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cervomed-announces-oral-presentation-at-19th-international-conference-on-alzheimers-and-parkinsons-diseases-and-related-neurologic-disorders-ap-pd\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cervomed-announces-oral-presentation-at-19th-international-conference-on-alzheimers-and-parkinsons-diseases-and-related-neurologic-disorders-ap-pd\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQwOTg5MyM2ODMxNTc5IzUwMDEyMTE2MA==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQwOTg5MyM2ODMxNTc5IzUwMDEyMTE2MA=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cervomed-announces-oral-presentation-at-19th-international-conference-on-alzheimers-and-parkinsons-diseases-and-related-neurologic-disorders-ap-pd\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer\u2019s and Parkinson\u2019s Diseases and Related Neurologic Disorders (AP\/PD\u2122)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/829378","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=829378"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/829378\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=829378"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=829378"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=829378"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}